Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 628.00

-2.2%

Nov 4 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: DewDiligence_on_SI	1/28/2022 7:23:26 PM
	of 3557

FDA approves Vabysmo—Roche’s bispecific mAb—for_wet AMD/DME: businesswire.com Vabysmo (a/k/a faricimab) inhibits VEGF-A and angiopoietin-2 (Ang-2). Dosing is every 1-4 months, based on patient response, following four monthly loading doses.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next